Li, J., Li, Z., Li, C., He, P., Luo, J., Fu, R., Zhong, L., Quach, H., Hocking, J., Presgrave, P., Tang, X., Zhang, W., Gao, J., Ding, L., Li, P., Zhou, H., Liu, P. (2025). Initial Results of the first-in-human Phase 1 study of IBI3003, a novel trispecific antibody targeting GPRC5D, BCMA and CD3, in patients with relapsed or refractory multiple myeloma. Blood. https://doi.org/10.1182/blood-2025-702